2 Sources
[1]
nference and Novo Partner to Advance Understanding of Cardiometabolic Disease and Healthy Ageing | Newswise
* Collaboration combines clinical trial and real-world insights to increase understanding of cardiometabolic disease * Research programs will aim to advance clinical pharmacology, combination therapies, and precision trials that track weight loss alongside whole-body health metrics * A parallel
[2]
Nference Announces Strategic Collaboration with Novo Nordisk to Advance Understanding of Cardiometabolic Disease and Healthy Ageing
nference announced that it has entered into a strategic collaboration with Novo Nordisk to advance research in cardiometabolic disease, including conditions such as obesity, diabetes, and cardiovascular disease. The partnership will bring together Novo Nordisk's clinical trial data and nference's
Share
Copy Link
nference, a Cambridge, Massachusetts company that builds AI infrastructure for biomedical research, announced a strategic collaboration with Novo Nordisk on November 18, 2026, to advance the study of cardiometabolic disease, including obesity, diabetes and cardiovascular disease
2
1
.The companies say pooling Novo Nordisk's clinical trial data with nference's AI tools and data network will deepen understanding of cardiometabolic disease and help generate evidence for future treatments
2
1
. Researchers from both companies plan to study how well treatments work, their safety, how diseases progress and health over the long term2
1
. The work draws on clinical studies, medical records and diagnostic data under privacy and governance safeguards2
1
.nference's AI platform is intended to sift that data for patterns in how diseases progress and how treatments perform in the real world, information that could shape future therapies
2
1
.nference says it already holds long-term data partnerships with major academic medical centers, including Mayo Clinic and Duke Health
1
. Novo Nordisk, for its part, traces a century of work in metabolic medicine1
. Venky Soundararajan, nference's founder and co-CEO, called the partnership an honor, pointing to that heritage1
. Novo's Jacob Sten Petersen, who leads R&D external innovation, said: "We see a significant opportunity to use AI and data to deepen our understanding of cardiometabolic disease and help improve future treatments."1
The collaboration also includes a framework for exploring potential new health-focused ventures, aimed at AI-native companies working on gaps in cardiometabolic health and healthy ageing
1
. No ventures have been announced; the framework, as described, is for exploring whether any potential ones should be.Related Stories
Summarized by
Navi
[1]
14 Apr 2026•Technology

16 Sept 2026•Technology

11 Oct 2024•Business and Economy
